Polymeric bile acid ester nanoparticles to induce tolerance
AssigneeYale University
InventorsJung Seok Lee, Tarek M. Fahmy, Dongin Kim
Life of this patent
Estimating the term…
Abstract
Polymeric bile acid (pBA) nanoparticles and tolerogenic formulation containing polymeric bile acid nanoparticles for oral delivery and induction of antigen-specific tolerance in a subject may include immunosuppressants and/or disease-specific antigen. Oral delivery results in local organ accumulation as well as systemic delivery of the nanoparticles. Early intervention with the nanoparticles induces antigen-specific tolerance and prevents development of autoimmune disorders. Treatment with the nanoparticles results in long-term antigen-specific immune tolerance, even after cessation of treatment, in autoimmune diseases.
Claims28
A formulation for inducing antigen-specific tolerance or non-specific decreased inflammation in a subject comprising
- an effective amount of nanoparticles comprising bile acid esterified polymers having a molecular weight between about 800 and 240,000 Dalton (Da),
- an immunomodulatory agent that decreases an immune response to an antigen, decreases inflammation or increases regulatory T cells, and, optionally, an antigen associated with an undesirable immune response.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.